期刊
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
卷 12, 期 12, 页码 2150-2157出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138920111798808347
关键词
Transforming growth factor beta; signaling pathway; gliomagenesis; high-grade glioma; antisense; oligonucleotide
High-grade gliomas are the most common primary tumors in the central nervous system (CNS) in adults. Despite efforts to improve treatment by combination therapies (neurosurgery, radio- and chemotherapy), high-grade glioma patients still have a grim prognosis, indicating an urgent need for new therapeutic approaches. The molecular processes of gliomagenesis are being unraveled, and novel targeted therapeutic strategies to defy high-grade gliomas are emerging. Transforming growth factor-beta (TGF-beta), in particular the TGF-beta 2 isoform, has been identified as a key factor in the progression of malignant gliomas. TGF-beta 2, originally described as glioblastoma-derived T-cell suppressor factor, is associated with the immuno-suppressed status of patients with glioblastoma, and is therefore responsible for loss of tumor immune surveillance. Elevated TGF-beta 2 levels in tumors and in the plasma of patients have been associated with advanced disease stage and poor prognosis. Consequently, a targeted strategy to modulate TGF-beta 2 signaling is highly promising. The antisense oligonucleotide trabedersen (AP 12009) that specifically blocks TGF-beta 2 mRNA will be the main focus of this review. In three phase I/II studies and a randomized, active-controlled dose-finding phase IIb study, trabedersen treatment of high-grade glioma patients with recurrent or refractory tumor disease led to long-lasting tumor responses and so far promising survival data. On the basis of these data the currently ongoing phase III study SAPHIRRE was initiated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据